Slow-release 5-amino-salicylic acid (Pentasa) for the treatment of active Crohn's disease
- PMID: 2190851
- DOI: 10.1159/000200228
Slow-release 5-amino-salicylic acid (Pentasa) for the treatment of active Crohn's disease
Abstract
A double-blind, placebo-controlled trial of a slow-release preparation of 5-amino-salicylic acid (Pentasa) has been performed in 40 patients with active Crohn's disease. Over a 6-week period, Pentasa (1.5 g daily) was no different to the dummy tablet in terms of clinical activity (Harvey-Bradshaw Index) or laboratory indicators of inflammation. No serious adverse reactions occurred.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
